Stockscreener 앱 받기
19.91
1.32%
0.26
전일 마감가:
$19.65
열려 있는:
$19.59
하루 거래량:
1.68M
Relative Volume:
0.50
시가총액:
$6.93B
수익:
$3.05B
순이익/손실:
$181.32M
주가수익비율:
53.38
EPS:
0.373
순현금흐름:
$186.11M
1주 성능:
-1.92%
1개월 성능:
+15.42%
6개월 성능:
+55.55%
1년 성능:
+93.49%
1일 변동 폭
$19.53
$19.93
1주일 범위
$18.97
$20.60
52주 변동 폭
$9.56
$21.18
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
(908) 947-3120
주소
-
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
19.91 | 6.93B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
18.73 | 59.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.10 | 47.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.32 | 40.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.81 | 30.91B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.16 | 23.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-23 | 개시 | Oppenheimer | Outperform |
| 2026-09-09 | 개시 | Leerink Partners | Outperform |
| 2026-04-17 | 개시 | UBS | Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com UK
Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to Trust - Kalkine Media
Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he oversees - Stock Titan
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - goSkagit
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - postregister.com
Amneal Pharmaceuticals, Inc.Class A Common Stock (NQ: AMRX - The Chronicle-Journal
Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target - marketscreener.com
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns - Reuters
Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares - scanx.trade
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
ZLAB Stock Price, Quote & News - Syfe
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Amneal builds end-to-end biosimilars capacity in the U.S. - chaindrugreview.com
Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich - sahmcapital.com
Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - vinanet.vn
Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance - Sahm
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance
AMRX Q2 2026 Earnings: Strong EPS Beat Drives 5.1% RallyEarnings Revision Upgrade - vinanet.vn
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan
AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan
Amneal Pharmaceuticals Insider Sold Shares Worth $2,563,517, According to a Recent SEC Filing - Yahoo Finance
Amneal Pharmaceuticals Insider Sold Shares Worth $3,771,050, According to a Recent SEC Filing - Yahoo Finance
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amneal Pharmaceuticals Inc 주식 (AMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kiely John | Director |
Aug 13 '26 |
Sale |
17.64 |
50,000 |
882,000 |
210,252 |
| JOHN KIELY | Director |
Aug 13 '26 |
Proposed Sale |
17.59 |
50,000 |
879,714 |
0 |
| NIKITA SHAH | Officer |
Aug 12 '26 |
Proposed Sale |
17.47 |
146,403 |
2,556,975 |
0 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 12 '26 |
Sale |
17.40 |
210,000 |
3,654,000 |
35,171 |
| Shah Nikita | Executive Vice President |
Aug 12 '26 |
Sale |
17.51 |
146,403 |
2,563,517 |
253,390 |
| BUCHI J KEVIN | Director |
Aug 11 '26 |
Proposed Sale |
17.31 |
168,573 |
2,917,998 |
0 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 11 '26 |
Sale |
17.70 |
6,613 |
117,050 |
245,171 |
| JASON DALY | OFFICER |
Aug 11 '26 |
Proposed Sale |
17.36 |
210,000 |
3,646,285 |
0 |
| Autor Deborah M. | Director |
May 11 '26 |
Sale |
12.94 |
34,819 |
450,558 |
93,660 |
| DEBORAH AUTOR | DIRECTOR |
May 11 '26 |
Proposed Sale |
12.94 |
34,819 |
450,416 |
0 |
1.25%
3.67%
자본화:
|
볼륨(24시간):